219 related articles for article (PubMed ID: 20485106)
1. Outliers on the dose-response curve: how to minimize this problem using therapeutic drug monitoring, an underutilized tool in psychiatry.
Preskorn SH
J Psychiatr Pract; 2010 May; 16(3):177-82. PubMed ID: 20485106
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic drug monitoring. Principles and practice.
Preskorn SH; Burke MJ; Fast GA
Psychiatr Clin North Am; 1993 Sep; 16(3):611-45. PubMed ID: 8415237
[TBL] [Abstract][Full Text] [Related]
3. [Therapeutic drug monitoring: A pharmacotherapeutic tool in psychiatry].
Stephan PL; Etzensberger M; Jaquenoud Sirot E
Praxis (Bern 1994); 2006 Apr; 95(17):671-8. PubMed ID: 16686323
[TBL] [Abstract][Full Text] [Related]
4. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry.
Baumann P; Hiemke C; Ulrich S; Eckermann G; Gaertner I; Gerlach M; Kuss HJ; Laux G; Müller-Oerlinghausen B; Rao ML; Riederer P; Zernig G;
Pharmacopsychiatry; 2004 Nov; 37(6):243-65. PubMed ID: 15551191
[TBL] [Abstract][Full Text] [Related]
5. Hypotension caused by therapeutic doses of venlafaxine: case report and proposed pathophysiological mechanisms.
Alexandrino-Silva C; Nadalini Mauá FH; de Andrade AG; de Toledo Ferraz Alves TC
J Psychopharmacol; 2008 Mar; 22(2):214-6. PubMed ID: 18208934
[TBL] [Abstract][Full Text] [Related]
6. Understanding outliers on the usual dose-response curve: venlafaxine as a way to phenotype patients in terms of their CYP 2D6 status and why it matters.
Preskorn SH
J Psychiatr Pract; 2010 Jan; 16(1):46-9. PubMed ID: 20098230
[TBL] [Abstract][Full Text] [Related]
7. [Therapeutic drug monitoring (TDM) of psychotropic drugs: a consensus guideline of the AGNP-TDM group].
Baumann P; Hiemke C; Ulrich S; Eckermann G; Kuss HL; Laux G; Müller-Oerlingenhausen B; Rao ML; Riederer P; Zernig G; ;
Rev Med Suisse; 2006 May; 2(67):1413-8, 1420-2, 1424-6. PubMed ID: 16786958
[TBL] [Abstract][Full Text] [Related]
8. Critical use of venlafaxine serology to uncover genetic rapid metabolism.
Schaller JL; Behar D
J Neuropsychiatry Clin Neurosci; 2001; 13(1):112-3. PubMed ID: 11207339
[No Abstract] [Full Text] [Related]
9. Pharmacokinetics and therapeutic drug monitoring of psychotropic drugs in pediatrics.
Pichini S; Papaseit E; Joya X; Vall O; Farré M; Garcia-Algar O; de laTorre R
Ther Drug Monit; 2009 Jun; 31(3):283-318. PubMed ID: 19363463
[TBL] [Abstract][Full Text] [Related]
10. Current applications of clinical genetic testing for psychiatric practice.
Mrazek DA
Minn Med; 2007 Jan; 90(1):42-3. PubMed ID: 17305105
[TBL] [Abstract][Full Text] [Related]
11. [Therapeutic drug monitoring in child and adolescent psychiatry--practical recommendations].
Gerlach M; Rothenhöfer S; Mehler-Wex C; Fegert JM; Schulz E; Wewetzer C; Warnke A
Z Kinder Jugendpsychiatr Psychother; 2006 Jan; 34(1):5-13. PubMed ID: 16485609
[TBL] [Abstract][Full Text] [Related]
12. [Therapeutic drug monitoring in epileptology and psychiatry].
Brandt C; Baumann P; Eckermann G; Hiemke C; May TW; Rambeck B; Pohlmann-Eden B
Nervenarzt; 2008 Feb; 79(2):167-74. PubMed ID: 17701390
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic drug monitoring in Italian psychiatry.
Conca A; Schmidt E; Pastore M; Hiemke C; Duffy D; Giupponi G
Pharmacopsychiatry; 2011 Sep; 44(6):259-62. PubMed ID: 21959788
[TBL] [Abstract][Full Text] [Related]
14. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011.
Hiemke C; Baumann P; Bergemann N; Conca A; Dietmaier O; Egberts K; Fric M; Gerlach M; Greiner C; Gründer G; Haen E; Havemann-Reinecke U; Jaquenoud Sirot E; Kirchherr H; Laux G; Lutz UC; Messer T; Müller MJ; Pfuhlmann B; Rambeck B; Riederer P; Schoppek B; Stingl J; Uhr M; Ulrich S; Waschgler R; Zernig G
Pharmacopsychiatry; 2011 Sep; 44(6):195-235. PubMed ID: 22053351
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic drug monitoring of psychoactive drugs during pregnancy in the genomic era: challenges and opportunities.
DeVane CL; Stowe ZN; Donovan JL; Newport DJ; Pennell PB; Ritchie JC; Owens MJ; Wang JS
J Psychopharmacol; 2006 Jul; 20(4 Suppl):54-9. PubMed ID: 16785271
[TBL] [Abstract][Full Text] [Related]
16. Polypharmacy: when is it rational?
Preskorn SH; Lacey RL
J Psychiatr Pract; 2007 Mar; 13(2):97-105. PubMed ID: 17414685
[TBL] [Abstract][Full Text] [Related]
17. Is pharmacogenetic CYP2D6 testing useful?
Vetti HH; Molven A; Eliassen AK; Steen VM
Tidsskr Nor Laegeforen; 2010 Nov; 130(22):2224-8. PubMed ID: 21109842
[TBL] [Abstract][Full Text] [Related]
18. The impact of cytochrome P450-2D6 genotype on the use and interpretation of therapeutic drug monitoring in long-stay patients treated with antidepressant and antipsychotic drugs in daily psychiatric practice.
Mulder H; Herder A; Wilmink FW; Tamminga WJ; Belitser SV; Egberts AC
Pharmacoepidemiol Drug Saf; 2006 Feb; 15(2):107-14. PubMed ID: 16294366
[TBL] [Abstract][Full Text] [Related]
19. Do guidelines recommending pharmacogenetic testing of psychiatric patients affect treatment costs and the use of healthcare services?
Herbild L; Bech M; Gyrd-Hansen D; Christensen M; Werge T; Nielsen KA
Scand J Public Health; 2011 Mar; 39(2):147-55. PubMed ID: 21257648
[TBL] [Abstract][Full Text] [Related]
20. CYP2D6 genotype and venlafaxine-XR concentrations in depressed elderly.
Whyte EM; Romkes M; Mulsant BH; Kirshne MA; Begley AE; Reynolds CF; Pollock BG
Int J Geriatr Psychiatry; 2006 Jun; 21(6):542-9. PubMed ID: 16642541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
